Shopping Cart
Remove All
Your shopping cart is currently empty
SRPKIN-1 is a covalent and irreversible inhibitor of SRPK1/2 (IC50s: 35.6 and 98 nM, respectively).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $1,170 | 6-8 weeks | 6-8 weeks | |
| 25 mg | $1,969 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $2,380 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $3,100 | 6-8 weeks | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $1,289 | 6-8 weeks | 6-8 weeks |
| Description | SRPKIN-1 is a covalent and irreversible inhibitor of SRPK1/2 (IC50s: 35.6 and 98 nM, respectively). |
| Targets&IC50 | SRPK1:35.6 nM, SRPK2:98 nM |
| In vitro | SRPK-IN-1 effectively converts VEGF from pro-angiogenic to anti-angiogenic isoform. SRPKIN-1 treatment at 200 nM (10, 50, 100, 200 nM, 16 hours) obviously decreases SR protein phosphorylation at the steady-state with or without washout [1]. |
| In vivo | SRPKIN-1 (50 nM, 300 nM,1 μL, 5 times) blocks angiogenesis through VEGF alternative splicing in a CNV mouse model [1]. |
| Molecular Weight | 472.53 |
| Formula | C27H21FN2O3S |
| Cas No. | 2089226-94-6 |
| Relative Density. | 1.43 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 110 mg/mL (232.79 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.